Risk of Birth Defects from WHO-Approved HIV Drug Delays Rollout

South Africa's national health department has been forced to postpone a nationwide rollout of dolutegravir over persistent concerns about what may be a low risk of birth defects linked to the drug's use. This comes after the World Health Organisation greenlit global use of the treatment in July.

Dolutegravir, a drug previously feared to cause deformities in unborn children, is now the preferred HIV treatment option, even among women of reproductive age.


Don't Miss

AllAfrica publishes around 900 reports a day from more than 130 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.